Skip to main content
Premium Trial:

Request an Annual Quote

Nasdaq to Suspend Trading of BG Medicine's Stock

NEW YORK (GenomeWeb) – BG Medicine today announced that its stock will be suspended from trading on the Nasdaq effective Sept. 16. 

Its shares will begin trading on that day on the OTC Markets OTCQB market under ticker symbol "BGMD." 

BG Medicine said that Nasdaq notified it on Monday of the suspension resulting from the firm's continuing non-compliance with a listing requirement calling for a minimum $2.5 million in stockholders' equity or a market capitalization of at least $35 million. The company was warned by Nasdaq of its listing deficiency in November 2014.

BG Medicine had until Sept. 10 to remedy its listing deficiency. The firm said that it understands that its stock will be delisted from the Nasdaq "after all applicable review and appeal periods have lapsed."  

In afternoon trading today, BG Medicine's shares were down 24 percent at $.49. 

The Scan

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.

Study Looks at Parent Uncertainties After Children's Severe Combined Immunodeficiency Diagnoses

A qualitative study in EJHG looks at personal, practical, scientific, and existential uncertainties in parents as their children go through SCID diagnoses, treatment, and post-treatment stages.

Antimicrobial Resistance Study Highlights Key Protein Domains

By screening diverse versions of an outer membrane porin protein in Vibrio cholerae, researchers in PLOS Genetics flagged protein domain regions influencing antimicrobial resistance.

Latent HIV Found in White Blood Cells of Individuals on Long-Term Treatments

Researchers in Nature Microbiology find HIV genetic material in monocyte white blood cells and in macrophages that differentiated from them in individuals on HIV-suppressive treatment.